Skip to main navigation Skip to search Skip to main content

A Phase II, Open-Label, Randomized, Multicentre Trial of GW786034(Pazopanib) in combination with Lapatinib (GW572016) compared to Lapatnib alone as first line of Therapy in Subjects with Advanced or Metastatic Breast Cancer with ErbB2 Fluor

Project Details

Short titleA Phase II, Open-Label, Randomized, Multicentre Trial of GW786034(Pazopanib) in combination with Lapatinib (GW572016) compared to Lapatnib alone as first line of Therapy in Subjects with Advanced or Metastatic Breast Cancer with ErbB2 Fluor
StatusFinished
Effective start/end date1/01/07 → 30/06/09

Funding

  • Queen Elizabeth Hospital